Answers are grounded in this paper and cite their sources.
Purpose Paraquat (PQ) is a highly toxic herbicide that induces hepatic injury through oxidative stress, inflammasome activation, and progressive fibrosis, contributing to chronic liver disease. Drug repurposing offers a promising strategy for accelerating therapeutic development. This study evaluated the hepatoprotective and antifibrotic potential of disulfiram (DSF), a clinically approved drug with emerging antioxidant and anti-inflammatory properties, against PQ-induced hepatic injury, including its association with NLRP3 inflammasome activation and PGC-1α expression. Methods Thirty-five male Wistar rats were randomly assigned to seven groups: Control, Vehicle, DSF20, PQ (1.5 mg/kg), and PQ co-treated with DSF (5, 10, or 20 mg/kg). PQ and DSF were administered via intraperitoneal injection for 4 weeks (5 consecutive days per week, with 2-day intervals). Hepatic injury was evaluated using histopathology (H&E and Masson's trichrome staining), serum biomarkers (ALT, AST, and ALP), oxidative stress parameters (malondialdehyde [MDA], catalase [CAT], and glutathione peroxidase [GPx]), NLRP3 and PGC-1α gene expression determined by qRT-PCR, and quantitative fibrosis assessment (fibrosis score and fibrotic area percentage). Results PQ exposure caused marked hepatic histopathological injury, increased oxidative stress, elevated liver enzymes, increased NLRP3 expression, decreased PGC-1α expression, and elevated fibrosis. DSF co-treatment, particularly at 20 mg/kg, significantly ameliorated these changes by reducing tissue injury, lowering lipid peroxidation, restoring antioxidant enzyme activity, suppressing NLRP3 expression, restoring PGC-1α expression, and decreasing fibrosis score and fibrotic area. Notably, NLRP3 suppression was effective at both 10 and 20 mg/kg, whereas a significant reduction in fibrosis required 20 mg/kg. Conclusion Disulfiram, particularly at 20 mg/kg, significantly attenuated PQ-induced hepatic injury and fibrotic remodeling, accompanied by reduced oxidative stress, suppression of NLRP3 expression, and restoration of PGC-1α expression.
No takes yet. Share an insight, caveat, or question.
Kandelousi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: